BAUSCH HEALTH COS INC (BHC.CA) Stock Fundamental Analysis
Canada - TSX:BHC - CA0717341071 - Common Stock
8.82 CAD
-0.45 (-4.85%)
Overall BHC gets a fundamental rating of 4 out of 10. We evaluated BHC against 32 industry peers in the Pharmaceuticals industry. While BHC is still in line with the averages on profitability rating, there are concerns on its financial health. BHC is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BHC was profitable.
BHC had a positive operating cash flow in the past year.
In the past 5 years BHC always reported negative net income.
BHC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BHC has a Return On Assets of 1.35%. This is in the better half of the industry: BHC outperforms 77.42% of its industry peers.
The Return On Invested Capital of BHC (6.78%) is better than 87.10% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BHC is below the industry average of 7.63%.
The 3 year average ROIC (5.45%) for BHC is below the current ROIC(6.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | N/A | ||
| ROIC | 6.78% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.45%
ROIC(5y)4.93%
1.3 Margins
The Profit Margin of BHC (3.61%) is better than 80.65% of its industry peers.
With an excellent Operating Margin value of 20.68%, BHC belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
BHC's Operating Margin has improved in the last couple of years.
BHC has a Gross Margin of 70.67%. This is amongst the best in the industry. BHC outperforms 90.32% of its industry peers.
In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.68% | ||
| PM (TTM) | 3.61% | ||
| GM | 70.67% |
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BHC is still creating some value.
The number of shares outstanding for BHC has been increased compared to 1 year ago.
The number of shares outstanding for BHC has been increased compared to 5 years ago.
Compared to 1 year ago, BHC has an improved debt to assets ratio.
2.2 Solvency
BHC has an Altman-Z score of 0.25. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.25, BHC is doing good in the industry, outperforming 61.29% of the companies in the same industry.
The Debt to FCF ratio of BHC is 19.41, which is on the high side as it means it would take BHC, 19.41 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BHC (19.41) is better than 67.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.41 | ||
| Altman-Z | 0.25 |
ROIC/WACC1.01
WACC6.69%
2.3 Liquidity
A Current Ratio of 1.30 indicates that BHC should not have too much problems paying its short term obligations.
With a Current ratio value of 1.30, BHC is not doing good in the industry: 67.74% of the companies in the same industry are doing better.
A Quick Ratio of 0.97 indicates that BHC may have some problems paying its short term obligations.
BHC has a worse Quick ratio (0.97) than 61.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 1.33% over the past year.
BHC shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -2.91% yearly.
Looking at the last year, BHC shows a small growth in Revenue. The Revenue has grown by 5.86% in the last year.
The Revenue has been growing slightly by 2.28% on average over the past years.
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
Revenue 1Y (TTM)5.86%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
3.2 Future
The Earnings Per Share is expected to decrease by -3.58% on average over the next years.
Based on estimates for the next years, BHC will show a decrease in Revenue. The Revenue will decrease by -0.40% on average per year.
EPS Next Y5.69%
EPS Next 2Y6.32%
EPS Next 3Y-1.71%
EPS Next 5Y-3.58%
Revenue Next Year6.13%
Revenue Next 2Y5.11%
Revenue Next 3Y3.03%
Revenue Next 5Y-0.4%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 1.65, the valuation of BHC can be described as very cheap.
Based on the Price/Earnings ratio, BHC is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.89, BHC is valued rather cheaply.
A Price/Forward Earnings ratio of 1.48 indicates a rather cheap valuation of BHC.
Based on the Price/Forward Earnings ratio, BHC is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 34.59. BHC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.65 | ||
| Fwd PE | 1.48 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 87.10% of the companies listed in the same industry.
100.00% of the companies in the same industry are more expensive than BHC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.15 | ||
| EV/EBITDA | 6.69 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BHC may justify a higher PE ratio.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y6.32%
EPS Next 3Y-1.71%
5. Dividend
5.1 Amount
BHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:BHC (11/14/2025, 7:00:00 PM)
8.82
-0.45 (-4.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.96%
Inst Owner ChangeN/A
Ins Owners10.81%
Ins Owner ChangeN/A
Market Cap3.26B
Revenue(TTM)10.03B
Net Income(TTM)362.00M
Analysts48.89
Price Target10.2 (15.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.24%
Min EPS beat(2)-7.07%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-8.49%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)4
Avg EPS beat(8)-3.92%
EPS beat(12)7
Avg EPS beat(12)-2.32%
EPS beat(16)8
Avg EPS beat(16)-5.93%
Revenue beat(2)2
Avg Revenue beat(2)0.5%
Min Revenue beat(2)0.36%
Max Revenue beat(2)0.64%
Revenue beat(4)3
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)0.64%
Revenue beat(8)6
Avg Revenue beat(8)0.85%
Revenue beat(12)9
Avg Revenue beat(12)1.1%
Revenue beat(16)9
Avg Revenue beat(16)-0.08%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.16%
EPS NQ rev (3m)-2.98%
EPS NY rev (1m)0.64%
EPS NY rev (3m)-12.22%
Revenue NQ rev (1m)-0.15%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.65 | ||
| Fwd PE | 1.48 | ||
| P/S | 0.23 | ||
| P/FCF | 2.15 | ||
| P/OCF | 1.54 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.69 |
EPS(TTM)5.36
EY60.77%
EPS(NY)5.97
Fwd EY67.74%
FCF(TTM)4.11
FCFY46.6%
OCF(TTM)5.71
OCFY64.74%
SpS38.02
BVpS-2.14
TBVpS-63.25
PEG (NY)0.29
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | N/A | ||
| ROCE | 9.41% | ||
| ROIC | 6.78% | ||
| ROICexc | 7.21% | ||
| ROICexgc | 32.42% | ||
| OM | 20.68% | ||
| PM (TTM) | 3.61% | ||
| GM | 70.67% | ||
| FCFM | 10.81% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.45%
ROIC(5y)4.93%
ROICexc(3y)5.7%
ROICexc(5y)5.13%
ROICexgc(3y)40.1%
ROICexgc(5y)34.22%
ROCE(3y)7.57%
ROCE(5y)6.85%
ROICexgc growth 3Y34.27%
ROICexgc growth 5Y-5.74%
ROICexc growth 3Y14.02%
ROICexc growth 5Y12.75%
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.41 | ||
| Debt/EBITDA | 6.2 | ||
| Cap/Depr | 34.45% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 45.65% | ||
| Profit Quality | 299.45% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 0.25 |
F-Score7
WACC6.69%
ROIC/WACC1.01
Cap/Depr(3y)22.53%
Cap/Depr(5y)20.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
EPS Next Y5.69%
EPS Next 2Y6.32%
EPS Next 3Y-1.71%
EPS Next 5Y-3.58%
Revenue 1Y (TTM)5.86%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
Revenue Next Year6.13%
Revenue Next 2Y5.11%
Revenue Next 3Y3.03%
Revenue Next 5Y-0.4%
EBIT growth 1Y18.58%
EBIT growth 3Y5.56%
EBIT growth 5Y6.8%
EBIT Next Year12.61%
EBIT Next 3Y9.06%
EBIT Next 5Y-1.3%
FCF growth 1Y21.39%
FCF growth 3Y3.22%
FCF growth 5Y0.55%
OCF growth 1Y34.83%
OCF growth 3Y3.85%
OCF growth 5Y1.25%
BAUSCH HEALTH COS INC / BHC.CA FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.CA.
What is the valuation status for BHC stock?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC.CA). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC.CA) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC.CA) is 3 / 10.